And while on vaccines, though it's not pertinent to India, Pfizer is working on an updated jab in response to the Omicron variant. The vaccine could be ready in 100 days, the head of the American multinational pharmaceutical giant, said.
Pfizer's chief executive Dr Albert Bourla told the BBC that he is of the view that annual vaccinations would be needed to maintain a "very high level of protection" against the deadly disease that has claimed over five million lives across the world.
Bourla was speaking to the BBC before the emergence of the Omicron variant, first identified in South Africa and also before the announcement that the UK government had signed contracts to buy the 54 million additional Pfizer-BioNTech and 60 million Moderna doses for 2022 and 2023.
These deals include access to modified vaccines if needed to combat Omicron and future variants of concern, the Department of Health has said.
Dr Bourla said Pfizer had already made updated vaccines in response to the Beta, also first identified in South Africa, and Delta, first identified in India, variants but that they had not been needed.
He said vaccines had helped save millions of lives during the pandemic, and without them, the "fundamental structure of our society would be threatened".
By the end of the year, Pfizer expects to have supplied three billion doses of its messenger ribonucleic-acid (mRNA) vaccine with four billion planned for next year.
Having to be stored at -70C, the Pfizer vaccine has been tricky to deploy in countries with limited health services.
But within a month or so, Pfizer says it will roll out a new formulation of the vaccine that can be stored for three months in a fridge, which Dr Bourla said, would make a "huge difference" for sub-Saharan African countries.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances
